Navigation Links
Questcor Reports First Quarter Financial Results
Date:4/30/2013

reimbursement levels from third party payers;
  • The complex nature of our manufacturing process and the potential for supply disruptions or other business disruptions;
  • The lack of patent protection for Acthar; and the possible FDA approval and market introduction of competitive products;
  • Our ability to continue to generate revenue from sales of Acthar to treat on-label indications associated with NS, MS, IS or rheumatology-related conditions, and our ability to develop other therapeutic uses for Acthar;
  • Research and development risks, including risks associated with Questcor's work in the area of NS and Lupus, our reliance on third-parties to conduct research and development, and the ability of research and development to generate successful results;
  • The results of any pending or future litigation, investigations or claims, including with respect to the investigation by the United States Attorney's Office for the Eastern District of Pennsylvania regarding the Company's promotional practices and litigation brought by certain shareholders arising from the federal securities laws, currently pending in the United States District Court for the Central District of California;
  • Our ability to comply with federal and state regulations, including regulations relating to pharmaceutical sales and marketing practices;
  • Regulatory changes or other policy actions by governmental authorities and other third parties in connection with U.S. health care reform or efforts to reduce federal and state government deficits;
  • An increase in the proportion of our Acthar unit sales comprised of Medicaid-eligible patients and government entities;
  • Our ability to estimate reserves required for Acthar used by government entities and Medicaid-eligible patients and the impact that unforeseen invoicing of historical Medicaid prescriptions may have upon our results;
  • Our ability to effectively manage our gr
    '/>"/>

  • SOURCE Questcor Pharmaceuticals, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

    Related medicine technology :

    1. Questcor to Report First Quarter Results on April 30, 2013
    2. Questcor Reports Fourth Quarter and Full Year 2012 Results
    3. Questcor to Report Fourth Quarter and Full Year 2012 Financial Results on February 26, 2013
    4. Questcor Pharmaceuticals Appoints Michael Aldridge to the Position of Senior Vice President, Corporate Strategic Development
    5. Questcor Pharmaceuticals Accelerates Cash Dividend; Payment Date Set for December 21, 2012
    6. Harwood Feffer LLP Announces Investigation of Questcor Pharmaceuticals, Inc.
    7. Questcor to Conduct Conference Call to Discuss Reimbursement Process
    8. Questcor Comments on Insurance Policy Bulletin
    9. Questcor and The Myositis Association Team Up To Support Research and Educational Initiatives in Polymyositis and Dermatomyositis
    10. Questcor Pharmaceuticals to Present at Investor Conferences in September
    11. Questcor Reports Second Quarter Financial Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:11/26/2014)... VIEJO, Calif. , Nov. 26, 2014 /PRNewswire/ ... announced that the U.S. Food and Drug Administration ... its New Drug Application (NDA) for AVP-825. AVP-825 ... low-dose sumatriptan powder delivered intranasally utilizing a novel ... the Complete Response letter, and consistent with the ...
    (Date:11/26/2014)... 26, 2014 Scott Steiger lives in ... world. As an engineer for the past 20 years, he,s traveled ... military service. He,s been to six of the seven continents. Travel ... - http://photos.prnewswire.com/prnh/20141126/161076 Photo - http://photos.prnewswire.com/prnh/20141126/161077 ... has a pretty good idea of what,s required. His ...
    (Date:11/26/2014)... 26, 2014 Zynerba Pharmaceuticals , Inc., ... innovative transdermal synthetic cannabinoid treatments, today announced that the ... Healthcare Conference 2014. The conference will be held December ... New York . Zynerba,s Chairman and ... pm on Tuesday, December 2. To listen ...
    Breaking Medicine Technology:Avanir Pharmaceuticals Receives Complete Response Letter (CRL) from FDA on AVP-825 NDA 2Avanir Pharmaceuticals Receives Complete Response Letter (CRL) from FDA on AVP-825 NDA 3Avanir Pharmaceuticals Receives Complete Response Letter (CRL) from FDA on AVP-825 NDA 4Steiger Has Created the First Pill Case Specifically Designed For Travel 2Zynerba Pharmaceuticals to Present at Piper Jaffray 26th Annual Healthcare Conference 2014 2
    ... Calif., Feb. 23, 2012 Anthera Pharmaceuticals, Inc. (Nasdaq: ... to treat serious diseases associated with inflammation and autoimmune ... and Chief Executive Officer, will provide a corporate presentation ... York, NY on Monday, February 27, 2012, at approximately ...
    ... Telik, Inc. (Nasdaq: TELK ) reported a net loss ... ended December 31, 2011, compared with a net loss of $9.8 ...  For the year ended December 31, 2011, net loss was $12.0 ... $24.7 million, or $0.46 per share, for the year ended December ...
    Cached Medicine Technology:Telik Announces Fourth Quarter and 2011 Year End Financial Results and 2012 Financial Guidance 2Telik Announces Fourth Quarter and 2011 Year End Financial Results and 2012 Financial Guidance 3Telik Announces Fourth Quarter and 2011 Year End Financial Results and 2012 Financial Guidance 4Telik Announces Fourth Quarter and 2011 Year End Financial Results and 2012 Financial Guidance 5Telik Announces Fourth Quarter and 2011 Year End Financial Results and 2012 Financial Guidance 6
    (Date:11/27/2014)... Randy Dotinga HealthDay Reporter ... brains seem pre-wired to acquire a second language, new research ... tongue will likely gain a brain boost, the small study ... after learning," said study co-author Ping Li, co-director of the ... But it,s even more interesting, Li said, that "the brain ...
    (Date:11/27/2014)... The founders of VIM & VIGR, a company ... compression socks, are proud to announce the debut of their ... Pressure (TM) knitting technology that is designed to increase the ... to adding flair and style to a product that has ... eye of a writer at The New York Times ...
    (Date:11/27/2014)... November 27, 2014 VogueQueen.com is making ... for ladies across the world. As the premier online ... VogueQueen.com is proud to release a huge selection of ... quality outfits, it is also providing many beautiful styles ... prom gowns at discounted prices. , “VogueQueen.com hopes ...
    (Date:11/27/2014)... Dallas, Texas (PRWEB) November 27, 2014 ... research report on Global Insulin industry. For an ... including definition, classification, application, industry chain structure, industry ... report on global Insulin industry covers information ... manufacturing process, product cost structure and much more. ...
    (Date:11/27/2014)... "The uglier, the better," says Dr. Kirk Kimmerling. ... laughter as we enjoy the ugly sweater contest." Last ... scratch. " It was a sight to see. She ... enough, the Christmas balls were faces of the staff with ... participating this year, it's simple to get in on the ...
    Breaking Medicine News(10 mins):Health News:Some People May Be Pre-Wired to Be Bilingual 2Health News:Some People May Be Pre-Wired to Be Bilingual 3Health News:VIM & VIGR Announces Launch of Men’s Line of Compression Socks 2Health News:A New Collection of Sexy Prom Dresses Has Been Released by the Reliable Online Supplier VogueQueen.com 2Health News:Insulin Industry Analysis (Supply, Consumption) for China, America, Korea, France & Japan Research Now at ReportsnReports 2Health News:Insulin Industry Analysis (Supply, Consumption) for China, America, Korea, France & Japan Research Now at ReportsnReports 3Health News:Verde Pointe Dental Associates Hosts 2014 Ugly Holiday Sweater Contest 2Health News:Verde Pointe Dental Associates Hosts 2014 Ugly Holiday Sweater Contest 3
    ... in German . , On 7 ... in Health Care (IQWiG) published the results of a ... heart disease (CHD). The aim of the report is ... methodological quality that may be relevant for the planned ...
    ... undergoing radiation treatments for head and neck cancer fare ... according to a study in the February issue of ... official journal of the American Society for Radiation Oncology ... smoking and head and neck cancers has long been ...
    ... have discovered a novel function of brain insulin, indicating that ... unrestrained lipolysis that initiates and worsens type 2 diabetes in ... Cell Metabolism . Led by Christoph Buettner, MD, ... and Bone Disease at Mount Sinai School of Medicine, the ...
    ... HealthDay Reporter , TUESDAY, Feb. 15 (HealthDay News) -- ... they,re first tested may not need to be screened annually ... study suggests. Dutch researchers presenting the findings at ... men with a PSA below 3.0 ng/ml were likely to ...
    ... Feb. 15 (HealthDay News) -- Men with prostate cancer may be ... baldness at the age of 20 than those without prostate cancer, ... hair in their 30s or 40s do not appear to face ... loss starts in their 20s do not face a higher risk ...
    ... more likely to be readmitted to the hospital after a ... pneumonia, according to a new study from Harvard School of ... rates were due to disparities related to both race and ... health and health care are well-documented in this country, but ...
    Cached Medicine News:Health News:DMP for coronary heart disease: Current guidelines indicate some need for revision 2Health News:DMP for coronary heart disease: Current guidelines indicate some need for revision 3Health News:Smoking during radiation treatments reduces chance of overall survival 2Health News:Researchers find brain insulin plays critical role in the development of diabetes 2Health News:PSA Test Cut-off Could Signal Low-Risk Prostate Cancer 2Health News:PSA Test Cut-off Could Signal Low-Risk Prostate Cancer 3Health News:Could Hair Loss at 20 Signal Higher Prostate Cancer Risk? 2Health News:Could Hair Loss at 20 Signal Higher Prostate Cancer Risk? 3Health News:Study finds blacks more likely to be readmitted to hospitals after discharge 2
    The Natural Selection family of specialty allografts are spinal allograft devices to eliminate the need for painful autograft harvesting....
    ... Corlok Allografts are unique corticocancellous allografts ... and a unique Dovetail geometry permitting ... vertebrae. Corlok Allografts are processed from ... allograft implants. Specially designed instruments facilitate ...
    Lumbar Allograft with Osteoactive advantage. Promotes bone formation and faster incorporation. Derived from the proven technology behind Grafton DBM. Maintains structural integrity and strength....
    ... Anteater Titanium Microdiscectomy System offers strength ... surgery. The boss anteater titanium microdiscectomy ... intervertebral discs provides for less invasive ... retractor is designed to provide low ...
    Medicine Products: